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A physiologically based kinetic 
model for elucidating the in vivo 
distribution of administered 
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Haolu Wang1,2,*, Xiaowen Liang1,*, Zhi Ping Xu3, Darrell H. G. Crawford4, Xin Liu1 & 
Michael S. Roberts1,5
Although mesenchymal stem cells (MSCs) present a promising tool in cell therapy for the treatment of 
various diseases, the in vivo distribution of administered MSCs has still been poorly understood, which 
hampers the precise prediction and evaluation of their therapeutic efficacy. Here, we developed the 
first model to characterize the physiological kinetics of administered MSCs based on direct visualization 
of cell spatiotemporal disposition by intravital microscopy and assessment of cell quantity using flow 
cytometry. This physiologically based kinetic model was validated with multiple external datasets, 
indicating potential inter-route and inter-species predictive capability. Our results suggest that the 
targeting efficiency of MSCs is determined by the lung retention and interaction between MSCs and 
target organs, including cell arrest, depletion and release. By adapting specific parameters, this model 
can be easily applied to abnormal conditions or other types of circulating cells for designing treatment 
protocols and guiding future experiments.
Mesenchymal stem cells (MSCs), also called multipotent mesenchymal stromal cells, are self-renewing, nonhe-
matopoietic somatic stem cells comparable to embryonic stem cells in terms of their multipotency and prolifer-
ative and differentiation potential. Due to their multilineage differentiation potential and immunomodulatory 
properties, MSCs present a promising tool in cell-based therapy for treatment of various nonhematopoietic dis-
eases, such as myocardial infarction, liver cirrhosis, spinal cord injury, cartilage damage and diabetes1–3. After the 
first clinical trial employing MSCs to treat osteogenesis imperfecta published in 19994, the number of registered 
clinical trials significantly increased, reaching 344 in 20135. Restoring the viability and function of MSCs in ana-
tomically complex organs (e.g. the liver, heart, and brain) remains a challenge for systematic MSC transplantation. 
Although functional improvements following the delivery of MSCs have been extensively explored in various dis-
eases, our current understanding of the in vivo behavior and distribution of administered MSCs is limited, which 
seems to hamper further transition of MSC transplantation from experimental trials to standard clinical pro-
cedures. Previous studies showed that most of MSCs were entrapped in the lung immediately after intravenous 
injection, with some MSCs undergoing apoptosis6. After about 10 min, these trapped MSCs gradually returned 
to the blood circulation and redistributed to other organs7. Finally only a small fraction of MSCs were found to 
survive, migrate to and engraft in the target organs. Thus, it would be important to characterize the in vivo dis-
tribution of MSCs following intravascular administration to predict their survival and homing to target organs6.
A number of published model have the potential to characterize the in vivo behavior of administered stem 
cells. The long-term replication, differentiation, or apoptosis of stem cells could be predicted by stochastic 
model8,9 or time-variant clustering model10. A computational cell motility model has been developed to probe 
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the migration mechanism of cells11. And the population dynamics of administered cells may be predicted using 
a recently developed mathematical model12. However, none of the above-mentioned published models could 
elucidate the concentration-time profiles of administered cells in organs. There is still a lack of a proper model to 
characterize the in vivo distribution of administered stem cells. It has been reported that the dynamics of system-
atically administered MSCs were similar to that of inert micrometer-scale particles injected into the bloodstream 
of animals13. Therefore the complex, yet regulated, in vivo kinetics of administered MSCs are amenable to phar-
macokinetic model building and analysis. During the past 30 years, physiologically based kinetic (PBK) models 
have been successfully applied to analyze the kinetics of small molecules, antibodies, nanoparticles and lym-
phocytes14,15. Such model is based on the anatomical structure of the living systems, with each important organ 
regarded as an individual compartment. All compartments are connected by blood flow14. Compared to empirical 
kinetic models, PBK modeling has the potential for interspecies scaling, which allows prediction of compound 
pharmacokinetics in humans using animal data. By systematically examining the effects of changing individual 
model parameters, PBK models can identify key parameters and their values, and suggest possible strategies for 
improvements in biodistribution. Therefore, quantitatively analyzing the in vivo distribution of MSCs with PBK 
modeling has the potential to identify the barriers to MSCs delivery, and propose designs of new formulations 
and dosing regimens to maximize the therapeutic activity.
In this study, we developed a simple PBK model to characterize the in vivo kinetics of MSCs from biodis-
tribution data of green fluorescent protein (GFP) expressed MSCs intravenously injected into mice. Being the 
first effort to model the distribution of administered stem cells, this model invoked assumptions based on direct 
visualization of MSCs in specific organs at the cellular level using high resolution multiphoton microscopy. The 
utility of the model was examined across species and administration routes by extrapolation of this model to rats 
and humans, as well as to intra-hepatic arterial injection. The clinical utility of the model was also tested with 
data obtained from stem cell-based therapies to patients with liver cirrhosis. This PBK model provides a general 
framework for the study of in vivo distribution of therapeutic cells to design treatment protocols and to guide 
future experiments.
Results
Disposition of MSCs at organ level. The spatiotemporal disposition of GFP-MSCs in organs at the cel-
lular level was explored using multiphoton microscopy (MPM). Figure 1A,B shows representative images of 
MSCs distribution in lung and liver at 30 min after intravenous injection. The MSCs were quickly observed in the 
microvessels of the lung and liver, instead of extravascular migrating into the surrounding collagens or alveoli 
of the lung and parenchyma of the liver. The size of MSCs was determined to be 20.1 ± 1.2 μm in mouse blood 
using MPM (Supplementary Fig. S1), and confirmed by bright-field microscopy (22.0 ± 2.6 μm, Supplementary 
Fig. S2). Some MSCs became passively entrapped in small-diameter blood vessels, and some were found to accu-
mulate and move in vessels with diameters greater than those of MSCs (Fig. 1B), suggesting the existence of both 
passive and active organ retention of MSCs. MSCs with smaller sizes (around 10 μm) were observed in organ 
capillaries (Fig. 1A), suggesting the possibility of MSC deformability which has been reported previously16. Few 
MSC was detected extravascular migrating up to 24 hours following intravenous injection. Figure 1C depicts the 
depletion process of one representative MSC in liver captured by real-time intravital imaging. After entrapped 
into the junction of the terminal portal venule and sinusoids (30 minutes post-injection), cell fragmentation was 
gradually observed with reduced fluorescence due to cell depletion.
Development of PBK model. The PBK model of MSCs in mice was developed based on the above observa-
tions and on the published intravital microscopic details of administered MSCs16–18. After intravenous injection, 
MSCs were transported to blood vessels of organs by organ blood flow via the systemic circulation. This process 
is assumed to be very fast. As shown in Fig. 2A, after reaching the organs, some MSCs became entrapped in 
microvessels due to their large sizes or temporarily adhered to the endothelial wall. A portion of these entrapped 
MSCs could be released back to the blood circulation or eliminated after depletion. These arrest-release-depletion 
processes were assumed to follow first-order kinetics with rate constants of karrest, krelease, and kdepletion, respectively. 
Tissue integration and differentiation of the arrested MSCs were not included in the model as these processes 
were much slower19,20 and had less impact on the MSC circulation and distribution at the organ level in the short 
term. All MSCs were assumed to act independently with no intercellular feedback loops or obligatory connec-
tions. For example, the entrapment of one MSC would not trigger the apoptosis or release of another. In summary, 
the in vivo kinetics of MSCs in this model was assumed to be governed by two processes: (1) transport to the 
organ via systematic circulation; (2) interaction with blood vessels of organs.
To build the PBK model, the whole body was separated into eight compartments: arterial blood, venous blood, 
lungs, spleen, liver, kidneys, heart and the rest of body. All compartments were interconnected via the systemic 
blood circulation (Fig. 2B). Key components included in the model were species-specific physiological parame-
ters (body weight, organ volume and blood flow, given in Supplementary Table S1) and MSC-specific parameters 
(partition coefficient, arrest rate constant, release rate constant and depletion rate constant).
Comparison of PBK model predictions with experimental data. After intravenous injection, the 
time profile of MSC levels in venous blood exhibited a two phase decay corresponding to a fast distribution 
and a relative slow elimination process. Lung, liver, spleen and kidney were major organs of MSC accumula-
tion. MSCs displayed different patterns of concentration-time profiles in these organs. As shown in Fig. 3, the 
observed time profiles of MSCs concentration in mouse blood and organs were adequately described by the 
developed PBK model with an overall regression coefficient (R2) of 0.966 (Supplementary Fig. S3), indicating high 
goodness-of-fit of model calibration results. However, despite the adequate overall predictions, it should be noted 
that the model predicted a rapid decrease of MSC concentration in blood within 5 min after injection. There is 
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Figure 1. Disposition of MSCs at organ level. (A) At 30 minutes post injection, the MSCs were found 
entrapped in the microvessels of the lung while no cell was found in the surrounding collagens or alveoli in 
the lung. Some MSCs less than 10 μm in diameter and may pass through the capillaries. (B) At 30 minutes 
post injection, some MSCs in liver were found accumulated and moving in vessels with diameters greater than 
those of MSCs and no cell was found extravasate into the liver parenchyma. (C) The depletion of MSC in the 
liver after intravenous injection. After entrapped at the junction of the terminal portal venule and sinusoids 
at 30 minutes post-injection, one MSC slowly became fragmented with reduced fluorescence suggestive of 
depletion. No MSCs was observed to cross the vessel membrane to the liver parenchyma. Images were recorded 
at λ Exc/λ Em: 740/350 to 450 nm for the endogenous autofluorescence of the lung and liver (red, left column), 
and λ Exc/λ Em: 900/450 to 515 nm for fluorescence of GFP (green, middle column). The right column represents 
fused images. Scale bar: 40 μm, and the white arrow points towards the MSCs with smaller sizes. A, alveoli; V, 
vessels; P, parenchyma; T, terminal portal venule.
www.nature.com/scientificreports/
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a lack of experimental data at this early time point to confirm this, which requires further experiments to either 
validate this prediction or revise the model accordingly.
Table 1 summarized the MSC-specific parameters for each organ. The highest arrest rate constant was 
obtained for the lung estimated by curve fitting (5.434 h−1), indicating that MSCs are predominantly entrapped in 
the lung after in vivo administration. Blood showed the highest depletion rate constant (0.636 h−1), suggesting its 
role as major elimination organ. The depletion rate constant in kidney was found to be highest among all organ 
compartments (0.151 h−1), which was consistent with the results from whole-body imaging and radioactivity 
counting of urine after injection of 99mTc labeled MSCs21. Our estimates suggest that about 28% of the trans-
planted MSCs survive in vivo 24 hours after intravenous injection. Similar survival rate have been obtained by 
intravital imaging of rat cremaster muscle microcirculation to track intraarterially delivered MSCs16.
To determine the effect of each parameter on the model simulation, a sensitivity analysis was performed. The 
relative sensitivity coefficient (RSC) for the concentration of MSCs in liver and heart are shown in Supplementary 
Fig. S4, because liver cirrhosis and myocardial infarction are two common diseases that have been treated with 
MSCs clinically. We selected 24 hours post-injection, when the amount of circulating MSCs decreased to a rela-
tively steady state. The concentration of MSCs in the liver at 24 h post injection was highly sensitive to the deple-
tion rate constant of liver, the release rate constant of lung, the partition coefficient and arrest rate constant of liver 
and lung. Similar effects of these parameters on the heart were observed. The depletion and arrest rate constant 
of heart, the arrest rate constant of lung, and the partition coefficient of heart and lung had a high impact on the 
concentration of MSCs in heart at 24 h post injection.
Model evaluation with independent rodent data. The validity of the PBK model was first evaluated 
with data from Shim et al.22 and Lee et al.7 where MSCs (5 × 105 and 2 × 106 cells) were intravenously admin-
istered to normal and diseased mice. All physiological parameters and MSC-specific parameters in the model 
were maintained constant. As shown in Fig. 4A,C,D, the model adequately predicted the MSC concentrations 
in blood in normal mice from the dataset of Shim et al.22, and MSC concentrations in lung and heart in normal 
mice from the dataset of Lee et al.7. However, as shown in Fig. 4B, the predicted MSC concentration in blood only 
slightly increased at about 3 min post-injection, while Lee et al. observed a much more substantial reappearance 
of MSCs in blood (2% to 3% of administered MSCs) after a lag period about 10 min7. A possible reason for this 
difference could be the different methods of MSC quantification, where the observed data were measured by 
quantitative assays for DNA of MSCs and our model was based on the data from flow cytometry analysis. Another 
reason is that mechanistic considerations, such as cell aggregation, changes in flow to organs, were not included 
in modeling, while these mechanisms might become more relevant to MSC distribution when higher concen-
tration are administered. In the dataset from Shim et al.22, the distribution of MSCs did not differ significantly 
between normal and osteoarthritis-induced mice. However, the model underestimated the MSC concentration 
in the heart with myocardial infarction from the dataset of Lee et al.7 (Fig. 4D), indicating the disease effect on 
MSC distribution. We then recalibrated the model to data from mice with myocardial infarction7, to estimate the 
diseases-specific heart-related parameters (Supplementary Table S2). As shown in Fig. 4D, the MSC concentration 
in the infarcted hearts was more accurately predicted by the same PBK mode with re-estimated diseased-specific 
parameters than with original parameters (the comparison of precision is shown in Supplementary Table S3). The 
Figure 2. Hypothesis and schematic diagram of the PBK model for the in vivo fate of MSCs.  
(A) Assumptions for modeling based on direct visualization of MSCs in specific organs at the cellular level using 
high resolution multiphoton microscopy. After intravenous injection, MSCs were transported to blood vessels 
of organs via systemic circulation. After reaching the organs, some MSCs became entrapped in microvessels 
due to large sizes or adhered to the endothelial wall. These MSCs could be released back to blood circulation or 
eliminated after depletion. The process of tissue integration and differentiation of the arrested MSCs was much 
slower extending from 24 to 72 hours post-injection. (B) Schematic diagram of the PBK model for the in vivo 
fate of MSCs. Solid arrows indicate blood flow, dashed grey arrows indicate the depletion of MSCs and grey 
boxes indicate the arrested MSCs isolated from blood circulation as in the extravascular space of organ.
www.nature.com/scientificreports/
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Figure 3. Model calibration results with experimental data. Mice were intravenously injected with 5 × 105 
MSCs (n = 5). The solid line in each panel represents the concentration-time profile of the MSCs simulated 
by the PBK model while the closed circles represent measured biodistribution data. Concentration of the 
MSCs is expressed as number of cells per kilogram of tissue. The data are expressed as mean ± s.d. The initial 
concentrations for organs (0 cell/L) are not shown because a base-10 log scale is used for the concentration.
Parameter (unit) Description Blood Lung Liver Spleen Kidney Heart
Rest of 
body
P (unitless) Partition coefficients – 742.733 262.699 1633.24 305.351 3.097 6.765
Karrest (h−1) Arrest rate constant – 5.434 1.395 0.608 1.727 1.251 0.143
Krelease (h−1) Release rate constant – 0.108 0.066 0.856 0.054 0.016 0.957
Kdepletion (h−1) Depletion rate constant 0.636 0.0589 0.060 0.002 0.151 0.039 0.148
Table 1.  MSC-specific parameters used in the PBK model estimated by curve fitting.
www.nature.com/scientificreports/
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re-estimation results indicated that higher concentration of MSC is related to higher arrest and less depletion of 
MSC in heart in disease status.
To further evaluate the predictive applicability of the PBK model across species, simulations were compared 
with published experimental data for rat21. Physiological parameters of rats (given in Supplementary Table S1) 
were obtained from literature23,24. MSC-specific parameters in the model were maintained constant. As shown 
in Fig. 5, the MSC concentrations in the lung, liver, spleen, kidneys and heart were predicted adequately by 
the model, but the blood levels were underestimated. It should be noted that MSCs in that study were 99mTc 
labeled and distribution was measured by nuclear imaging. Therefore, residual radioactivity of cell fragments in 
blood before excretion may result in overestimation of MSC concentration in nuclear imaging. In contrast, our 
model was based on the data from flow cytometry analysis, which largely reflected the concentration of live cells. 
Overall, there was a good correlation (R2 = 0.922) between PBK model estimates and independent rodent data 
(Supplementary Fig. S5), indicating that the model shown here is applicable to predict the in vivo distribution of 
administered MSCs across rodents. However, the time courses of this datasets have only two data points (2 hours 
and 20 hours) for each organ. More detailed data are needed to adequately evaluate the potential inter-species 
predictive capability of this model.
Model predicting the in vivo distribution of therapeutic stem cells in humans. This model was 
used to predict the in vivo distribution of the therapeutic stem cells in patients with liver cirrhosis after intrave-
nous or intra-hepatic arterial injection. Physiological parameters of humans (given in Supplementary Table S1) 
were obtained from literature23–25, MSC-specific parameters in the model were maintained constant. As shown 
in Fig. 6A, our model suggests that the time profiles of MSC concentration in liver significantly differ between 
patients after intravenous or intra-hepatic arterial injection of the same number (8.5 × 108) of MSCs. The model 
successfully predicted the proportion of bone marrow-derived mononuclear cells (BMMCs) in the liver to the 
whole body at 3 and 24 hours after injection for the data from Couto et al.26 (Fig. 6B). However, it underestimated 
the proportion of MSCs in the liver to the whole body after intra-hepatic arterial injection for the data from 
Gholamrezanezhad et al.27 (Fig. 6C). We then recalibrated the model to data from human with liver cirrhosis27, 
to estimate the diseases-specific liver-related parameters (Table S2). As shown in Fig. 6D, the MSC concentration 
in the cirrhotic liver was more accurately predicted by the same PBK mode with re-estimated diseased-specific 
parameters than with original parameters (the comparison of precision is shown in Supplementary Table S3). The 
re-estimation results indicated that higher concentration of MSC is related to higher partition and arrest of MSC 
in liver in disease status.
Figure 4. Model evaluation results with independent external datasets from mice. (A) Mice were 
intravenously injected with 5 × 105 MSCs22 (n = 5). (B–D) Mice were intravenously injected with 2 × 106 MSCs7 
(n = 6). The solid line in each panel represents the concentration-time profile of the MSCs simulated by the PBK 
model while the closed circles represent measured biodistribution data. Concentration of the MSCs is expressed 
as number of cells per kilogram of tissue. The data are expressed as mean ± s.d. The initial concentrations for 
organs (0 cell/L) are not shown because a base-10 log scale is used for the concentration.
www.nature.com/scientificreports/
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Discussion
Although hundreds of studies have reported the cell biodistribution in the field of stem cell-based therapy, no 
integrating model characterizing the in vivo kinetics of these cells has been developed with respect to pharma-
cological effects and therapeutic thresholds. In the present study, we developed a model based on direct visu-
alization of GFP-labeled MSCs disposition in the mice at the cellular level in specific organs. Importantly, the 
mouse cells used in this study were expanded to a similar size as the human MSCs currently used in clinical 
trials. Compared with the previously published PBK model of lymphocytes15, our model is especially applicable 
to circulating cells with large sizes (MSCs or cancer cells are 1.5 to 4 times larger than lymphocytes). This model 
is more useful for clinical applications since a less complicated framework and parameters were employed. In the 
Figure 5. Model evaluation results with independent external datasets from rats. Rats were intravenously 
injected with 3.2 × 106 MSCs21 (n = 9). The solid line in each panel represents the concentration-time profile 
of the MSCs simulated by the PBK model while the closed circles represent measured biodistribution data. 
Concentration of the MSCs is expressed as number of cells per kilogram of tissue. The data are expressed as 
mean ± s.d. The initial concentrations for organs (0 cell/L) are not shown because a base-10 log scale is used for 
the concentration.
www.nature.com/scientificreports/
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future, the predictive power of this model is likely to improve with the incorporation of new parameter values or 
advanced microscopic details as they become available.
One of the advantages of PBK modeling over traditional empirical kinetic modeling is the ability to provide 
time profiles of cell concentration in individual organs. The in vivo distribution of MSCs characterized mathe-
matically in the present study will better inform the dosing regimens of cell-based therapies. For example, it may 
be expected that higher administered numbers of MSCs should result in more MSC engraftment and better func-
tional outcomes. However, in a rat model of brain injury, no additional enhancement of neurological function was 
observed after increasing the dose of intravenous injected MSCs by 3-fold28. Thus, simply increasing the number 
of delivered cells may not improve the overall outcome. The sensitivity analysis of our PBK model showed that 
the accumulation of MSCs in the lung adversely affected the delivery of therapeutic cells to other target organs, 
evident by the concentrations of MSCs in the target organs were sensitive to changes in the partition coefficient, 
arrest or release rate constant in the lung. The partition coefficient, arrest and depletion rate constant in target 
organs also had a high impact on the concentration of MSCs. Thus, instead of increasing the dose, possible strate-
gies to further improve the target efficiency of cell-based therapies would be bypassing the initial lung entrapment 
and enhancing organ-specific capture by modulating cell surface properties.
Administration of MSCs into the arterial supply of the liver was examined in this study as an alternative route 
of intravenous injection to bypass lung entrapment. The inter-route extrapolation of this PBK model suggests that 
accumulation of MSCs in the liver significantly differs after intravenous and intra-hepatic arterial injection. Our 
PBK model confirmed that direct delivery of MSCs to the target organs may improve the therapeutic efficacy by 
increasing the accumulation of surviving cells in those organs. Compared to intravenous injection, transplanta-
tion via hepatic artery or portal vein could increase the amount of MSCs in the liver at 24 hours post-injection by 
4-fold in humans (Fig. 6A), in agreement with the therapeutic efficacy study of the MSCs treatment of fulminant 
hepatic failure in pigs29. Our PBK model also allows the scale-up from the mice data to humans. In many stud-
ies on cell therapy, an accurate concentration of cells in organs is not available from humans30. One should be 
Figure 6. Model evaluation results with independent external datasets from humans. (A) The PBK 
model suggests that the time profiles of MSC concentration in liver significantly differ between patients after 
intravenous or intra-hepatic arterial injection of the same number (8.5 × 108) of MSCs. (B) Patients were 
intra-hepatic arterially injected with an average of 8.5 × 108 radiolabeled BMMCs26 (n = 8). (C,D) Patients 
were intra-hepatic arterially injected with an average of 3.2 × 108 radiolabeled MSCs for 24 hours and 10 days, 
respectively27 (n = 4). The residual radioactivity in the liver is expressed as the proportion of the whole body 
radioactivity. The solid line in each panel represents the concentration-time profile of the cells simulated by 
the PBK model while the closed squares represent measured biodistribution data. The data are expressed as 
mean ± s.d.
www.nature.com/scientificreports/
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cautious in direct translation of the distribution results from mice to humans due to different concentration-time 
profiles of MSCs in organs between species. This PBK model could provide more accurate prediction by scaling 
up the profile from mice to human.
There is substantial evidence that administered MSCs would accumulate within sites of disease or injury. Local 
changes in microvessels and organ-derived attractants have been reported to affect the arrest and entrapment of 
MSCs in diseased organs17, while the time profiles of cell concentrations in unaffected organs may only slightly 
decrease21. Thus, parameter values of diseased organs in the PBK model would be different from normal organs. 
In the present model, MSC-specific parameters of diseased organs for myocardial infarction and liver cirrhosis 
were optimized separately from respective datasets, because these parameters were considered to be the most 
influential in the in vivo distribution of MSCs in disease, while other less influential parameters were kept the 
same. It would be of importance to investigate the MSC-specific parameters of target organs for each main type 
of diseases in the future.
In summary, we present the first model for characterizing and predicting the in vivo distribution of admin-
istered MSCs. Key ingredients in the model are species-specific physiological parameters (body weight, organ 
volume, blood volume and blood flow) and cell-specific parameters (partition coefficient, arrest rate, release 
rate and depletion rate). This model has been validated with multiple external datasets under widely different 
conditions and in different species, indicating potential inter-route and inter-species predictive capability. Based 
on our analysis, possible strategies to improve efficiency of cell-based therapies include bypassing the initial lung 
entrapment with administration to the arterial supply of target organs and enhancing organ-specific capture by 
modulating cell surface properties. This PBK model can be extended to other types of circulating cells by adapting 
the cell-specific parameters, and provides a general framework for the study of the in vivo distribution of thera-
peutic cells to design treatment protocols.
Experimental Procedures. Cell preparations. The mouse GFP-MSCs used in this study were kindly pro-
vided by Dr. Mike Doran (Queensland University of Technology). The MSCs were isolated, characterized and 
cultured from inbred C57BL/6 mice transgenic for GFP under the control of the ubiquitin promoter as previously 
described31,32. All experiments involving MSCs were performed at passage 8–12, tested negative for mycoplasma 
contamination, and < 80% confluence. The average diameter of suspended MSCs was measured from fifty differ-
ent cells from twelve representative image fields.
In vivo transplantation and imaging of MSCs. Male 20-week-old BALB/c nude mice were purchased from the 
Animal Resource Centre (Perth, Western Australia). All animal procedures were approved by the Animal Ethics 
Committee of the University of Queensland and were carried out in accordance with Australian Code for the Care 
and Use of Animals for Scientific Purposes 8th edition. Mice were anaesthetized initially by an intraperitoneally 
injection of ketamine hydrochloride (80 mg/kg) and xylazine (10 mg/kg). Body temperature was controlled by 
placing mice on a heating pad set to 37 °C. 150 μl of a suspension of 5 × 105 MSCs was injected with a 27 gauge 
needle through the tail vein. Prior to injection, the MSCs were maintained at 4 °C, and the cells were gently resus-
pended with a pipette to ensure no aggregation before injection.
MPM was performed using the DermaInspect system (Jen-Lab GmbH, Jena, Germany) equipped with an 
ultrashort (85 fs pulse width) pulsed mode-locked 80-MHz titanium sapphire laser (MaiTai, Spectra Physics, 
Mount View, CA, USA). The excitation wavelength was set to 740 nm for organ autofluorescence and 900 nm for 
GFP signals, with emission signal ranges of 350 to 450 nm and 450 to 515 nm established respectively through the 
use of BG39 bandpass filters (BG39, Schott glass color filter, Schott MG, Mainz, Germany). Images were recorded 
with oil-immersion 40x objectives (Carl Zeiss, Germany). The laser power was set to 15 mW for 40x magnifica-
tion imaging, and the acquisition time for obtaining the images was 7.4 seconds per frame. Intravital imaging of 
the mouse liver was performed as previously described33,34. Twenty-four images from twelve non-overlapping 
fields were collected per mouse (n = 5) without the use of randomization and blinding. Normal saline was used 
to keep the liver and other organs moist and attached to the cover glass throughout the experiment. Analysis and 
overlay of the fluorescence intensity images was done using ImageJ 1.44p (National Institutes of Health, USA). 
The diameter of cells was measured along three different arbitrary lines within a cell, and tested on eighteen dif-
ferent cells from six representative image fields.
Organ specimens from sites of MPM imaging were fixed in 4% buffered formalin and embedded in paraffin. 
Serial sections were obtained for Hematoxylin & Eosin (H&E) stain to evaluate histopathologic features. The 
OlyVIA software 2.6 (Olympus, Münster, Germany) was used to visualize and scan the slides.
Measurement of donor MSCs in recipient organs. Animals (n = 5) were sacrificed at designated times (5 min, 
15 min, 1, 3, 10, and 20 hour post-injection). The blood and major organs were removed and weighed. Red blood 
cells were lysed and single-cell suspensions of organs were obtained as previously described35. The total number 
of GFP-MSCs in each single-cell suspension of organs was measured and analyzed by flow cytometry using a 
FACS Calibur (Accuri C6, BD, San Jose, CA, USA) as previously described36. As negative controls, single-cell 
suspensions of organs from naive mice were run in parallel. Light scattering parameters were set to exclude dead 
cells and debris.
Mathematical description of the model. The model structure was based on published PBK models simulating 
the distribution (using distribution coefficient) and uptake-release-excretion processes (using uptake, release 
and excretion rate constant) of inert nanoparticles37. The model assumes a fast process of MSCs transported 
into various levels of blood vessels in organs. The partition coefficient P is used to correlate the concentration of 
MSCs between the blood within the organ and the venous blood leaving the organ. Given that the microvascular 
www.nature.com/scientificreports/
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environment varies between organs, the partition coefficient is assumed to be different between organs. The equa-
tion describing this correlation is:
= _CV
C
P (1)t
V t
t
where CVt (cell/L) is the concentration of MSCs in the venous blood leaving the organ t, CV_t (cell/L) is the con-
centration of MSCs in the vascular space within the organ t, Pt (unitless) is the partition coefficient of the organ t.
Since a fraction of MSCs could be arrested in organs and isolated from blood circulation, these MSCs are 
described separately as in the extravascular space of organ. In the blood and organs, elimination of MSCs 
after depletion occurs as a clearance route from the body. The arrest-release-depletion approach of MSCs was 
described as a first-order process. The equations describing these processes are:
For vascular space
= − − +_
_
_ _ _ _ _V
dC
dt
Q C CV K C V K A( ) (2)V t
V t
t A t arrest t V t V t release t E t
For the arrested MSCs as in the extravascular space
= − −_ _ _ _ _ _ _ _
dA
dt
K C V K A K A (3)
E t
arrest t V t V t release t E t depletion t E t
VV_t (L) is the volume of blood vessels in the organ t, Qt (L/h) is the blood flow to the organ t, CA (cell/L) is the 
concentration of MSCs in the arterial blood, AE_t (cell) is the amount of arrested MSCs and isolated from blood 
circulation as in the extravascular space of organ t, Karrest_t (h−1) is the arrest rate constant of MSCs in the organ t, 
Krelease_t (h−1) is the release rate constant of MSCs in the organ t, and Kdepletion_t (h−1) is the depletion rate constant 
of MSCs in the organ t. Mass balance equations used in the model are presented in the Supplementary Note.
Implementation and parameterization of the model. The PBK model was implemented in Berkeley Madonna 
version 8.3.18 (Berkeley, CA, USA). Mass balance equations used in the model are presented in the supplemen-
tary. All physiological parameter values (body weight, organ volume, blood volume and blood flow) were from 
the literature and are given in Table S1. MSC-specific parameters (partition coefficient, arrest rate constant, 
release rate constant and depletion rate constant) were optimized by using both curve fitter in Berkeley Madonna 
automatically and a manual approach to obtain a visually reasonable fit to the experimental biodistribution data 
of GFP- MSCs intravenously injected into mice.
Sensitivity analyses. To determine the effect of the parameters on the model solution, sensitivity analysis was 
performed for the parameters in the target organs. The value of each parameter was increased by 0.1%, the model 
simulations were repeated, and the new MSCs concentrations noted. The relative sensitivity coefficients for sig-
nificant parameters were calculated using the following equation:
=
dC C
dP P
Relative sensitivity coefficient /
/ (4)
where C (cell/L) is the concentration of MSCs, and P is the parameter value. A positive RSC indicates a direct 
association between the model output and the corresponding parameter, while a negative RSC suggests the model 
output is inversely correlated with the specific parameter. The RSC values with absolute values higher than 0.5 are 
considered as highly sensitive.
Model evaluation with independent data. The predictive capability of our PBK model was evaluated with exter-
nal datasets from different species7,21,22,26,27. To facilitate comparisons among the various studies, all concentra-
tions were normalized to the number of MSCs per kg of organ. The physiological parameter values of rats and 
humans were obtained from the literature and are given in Table S1. MSC-specific parameters were assumed to 
be the same for mice, rats and humans. The overall goodness-of-fit between predicted and measured values was 
further analyzed with linear regression. To compare the predictive capability of model with different parameters, 
bias (mean prediction error [MPE]) and precision (mean absolute prediction error [MAPE]) are calculated with 
95% confidence intervals (CIs) using the following equation:
=
∑ −
MPE
M M
N
( )
(5)
pred obs
=
∑| − |
MAPE
M M
N (6)
pred obs
where Mpred is the predicted value, Mobs is the observed value, and N is number of time points. The statistical anal-
ysis was done using GraphPad Prism v 6.04 (GraphPad Software Inc., La Jolla, California).
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